Here we show the experimental development of a CAR-NK therapy strategy against the IL2RA/CD25 which as described above has been previously reported as being overexpressed, in advanced CML (21). Here, IL2RA is linked to chronic myelogenous leukemia, BCR-ABL1 positive.